CE Approval to market new product

RNS Number : 7735X
Advanced Medical Solutions Grp PLC
02 September 2015

02 September 2015


Advanced Medical Solutions Group PLC

(“AMS” or the “Group”)


CE Approval received for antimicrobial foam dressing


Winsford, UK, 01 September 2015 – Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announces that it has received CE approval to market its Polyhexamethylene Biguanide (PHMB) non adhesive antimicrobial foam dressing in Europe.


PHMB has been shown to be effective against several bacteria including, amongst others, Staphylococcus Aureus including the methicillin resistant type, (MRSA) and Escherichia Coli (E-Coli). This antimicrobial foam wound dressing may be used throughout the healing process on moderate to heavily exuding chronic and acute wounds that are infected or are at risk of infection and may be used on pressure ulcers, leg and foot ulcers, diabetic ulcers and surgical wounds. 


AMS expects to launch this product through its OEM partners in 2015, as well as including it in its ActivHeal® range of woundcare dressings for the NHS.


Chris Meredith, Chief Executive Officer of AMS, commented: “We are pleased to receive CE approval for this AMS product which strengthens our position in the antimicrobial foam market and look forward to launching it in EU markets and into the NHS later this year.


– Ends –



For further information, please visit www.admedsol.com or contact:


Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys


Investec Bank plc (NOMAD) & Broker

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


About Advanced Medical Solutions Group plc – see www.admedsol.com


AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.


AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 470 employees. For more information please see www.admedsol.com.

This information is provided by RNS
The company news service from the London Stock Exchange